ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.05
-0.01 (-0.11%)
At close: Mar 9, 2026, 4:00 PM EDT
9.23
+0.18 (1.99%)
After-hours: Mar 9, 2026, 5:28 PM EDT

ARS Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Market Capitalization
8951,1521,025526800-
Upgrade
Market Cap Growth
-21.86%12.32%94.90%-34.23%--
Upgrade
Enterprise Value
7461,033821284839-
Upgrade
Last Close Price
9.0611.6510.555.488.53-
Upgrade
PE Ratio
--128.20---
Upgrade
PS Ratio
10.6113.6611.5017535.50607.80-
Upgrade
PB Ratio
7.8710.083.992.282.93-
Upgrade
P/TBV Ratio
8.9611.544.122.292.93-
Upgrade
P/FCF Ratio
--78.96---
Upgrade
P/OCF Ratio
--75.68---
Upgrade
EV/Sales Ratio
8.8512.269.219483.00637.20-
Upgrade
EV/FCF Ratio
--63.20---
Upgrade
Debt / Equity Ratio
0.840.840.270.000.000.20
Upgrade
Debt / FCF Ratio
--5.35---
Upgrade
Net Debt / Equity Ratio
-1.30-1.30-0.95-0.99-1.00-1.14
Upgrade
Net Debt / EBITDA Ratio
0.840.8481.423.387.962.65
Upgrade
Net Debt / FCF Ratio
0.870.87-18.843.846.802.90
Upgrade
Asset Turnover
0.250.250.3100.010.13
Upgrade
Inventory Turnover
3.013.01----
Upgrade
Quick Ratio
6.916.9113.7995.8050.597.34
Upgrade
Current Ratio
7.287.2814.2696.9251.017.42
Upgrade
Return on Equity (ROE)
-92.33%-92.33%3.28%-21.59%-21.84%-77.93%
Upgrade
Return on Assets (ROA)
-33.05%-33.05%-0.66%-16.40%-12.56%-27.68%
Upgrade
Return on Invested Capital (ROIC)
---40.01%-8134.94%--
Upgrade
Return on Capital Employed (ROCE)
-62.20%-62.20%-0.90%-29.30%-12.50%-36.50%
Upgrade
Earnings Yield
-19.15%-14.88%0.78%-10.33%-4.34%-
Upgrade
FCF Yield
-19.14%-14.87%1.27%-11.30%-5.04%-
Upgrade
Buyback Yield / Dilution
3.74%3.74%-7.54%-138.30%-38.39%-42.81%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.